Market Trends of Cell Dissociation Industry
The Pharmaceutical and Biotechnology Companies Segment is Expected to Witness Healthy Growth Over the Forecast Period
Biopharmaceutical companies are intensifying their focus on new drug development and ramping up R&D efforts, consequently driving up the demand for cell dissociation products.
An article from PubMed, released in March 2022, highlighted a surge in the demand for biopharmaceuticals. This surge catalyzed the rise of a new business model, the 'contract development manufacturing organization (CDMO),' designed to streamline biopharmaceutical development and production. CDMOs, equipped to handle larger production volumes, are adeptly meeting the industry's escalating demands.
As pharmaceutical and biopharmaceutical companies increasingly pivot toward cell-related therapies, their strategic R&D investments further fuel the demand for cell dissociation products, bolstering market growth.
In January 2024, AbbVie and Umoja Biopharma inked exclusive licensing deals to advance multiple in-situ generated CAR-T cell therapy candidates in oncology, leveraging Umoja's proprietary VivoVecTM platform.
In December 2023, Fujifilm made a substantial USD 200 million investment in cell therapy manufacturing. The fund was specifically allocated to a drug research segment that is expected to record significant growth in the years ahead. Such strategic moves by market players are pivotal in propelling the market's expansion.
Given the heightened R&D focus of pharmaceutical and biopharmaceutical entities, coupled with the surging demand for cell therapies, the pharmaceutical and biotechnology companies segment is poised for substantial growth in the coming years.
North America is Expected to Hold a Significant Market Share
The North American cell dissociation market is poised for significant growth, driven by the region's advanced biopharmaceutical industry, facilitating robust R&D for novel therapeutics. Heightened company investments in new therapies further bolster this trajectory.
Highlighted in the Cancer Facts & Figures 2024 report by the American Cancer Society, the US is projected to see around 2.0 million new cancer cases in 2024. This, coupled with a rising geriatric population and a surge in chronic diseases, particularly cancer, cardiovascular diseases (CVDs), and diabetes, underscores the nation's growing need for biopharmaceuticals, which is expected to boost market growth.
According to the Canadian Cancer Statistics 2023, unveiled in November 2023, around 239.1 thousand Canadians were expected to undergo a cancer diagnosis in 2023, further emphasizing the demand for innovative therapies and the resultant market growth.
The uptick in biopharmaceutical and cell therapy manufacturing facilities in North America is amplifying the need for cell dissociation products in various research and manufacturing processes. REPROCELL inaugurated a GMP Manufacturing Facility for Stem Cells in the US in May 2024. These developments underscore the market's upward growth trajectory.
The escalating disease burden and the proliferation of new cell-related manufacturing and research facilities are the primary drivers fueling the market's growth.
